Industry news that matters to you.  Learn more

Karmanos Cancer Institute Uses Definiens Tissue Studio for Biomarker Development

Reading time: 2 – 3 minutes

Definiens, the number one Health Image Intelligence company, today announced that the Barbara Ann Karmanos Cancer Institute in Detroit is using Definiens image analysis software in a new approach to cancer diagnosis and biomarker development. The Karmanos Cancer Institute is applying Definiens Tissue Studio 2.0TM, the newest version of the company’s leading image analysis software for digital pathology, to automate tissue section and microarray analysis. Led by Gerold Bepler, M.D., Ph.D., president and CEO of the Karmanos Cancer Institute, the research team will replace tedious manual analysis processes with automated image analysis to more reliably develop biomarkers that facilitate patient stratification models for personalized medicine applications.

“Automating image analysis in our research will significantly enhance our ability to apply knowledge of cancer characteristics to patient diagnosis and treatment,” said Dr. Bepler,. “We are using Definiens Tissue Studio to analyze cancer biomarkers on the cellular and sub-cellular levels. The software will help us classify tumors and generate better prognostic and predictive data. We expect this will improve our ability to stratify patients for the most promising clinical approach.”

The Karmanos Cancer Institute, based in midtown Detroit, is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for approximately 6,000 new patients annually on a budget of $216 million, and conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation’s best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate cancer.

Researchers at the Karmanos Cancer Institute aim to improve the speed and accuracy of diagnosis by automating image analysis of tissue sections stained for morphology and biomarker expression, as well as tissue microarrays measuring clinically relevant biomarkers. Definiens Tissue Studio will enable Dr. Bepler’s team to analyze cancers, including lung, breast and pancreatic cancer, on the cellular and sub-cellular level. Rapid and accurate quantification of cancer characteristics will enable the research team to translate knowledge to clinical applications.

“Definiens’ image analysis software is uniquely suited to the translational medicine demands of the Karmanos Cancer Institute,” said Thomas Colarusso, Vice President of North American Sales and Operations for Definiens. “Our digital pathology software will enable the Institute to automate biomarker analysis, providing quantitative data that can inform patient treatment decisions.”

Source: Definiens